Target intelligence / Profile preview

Human cutaneous antigen-presenting cells (APCs) (APCs)

Target
APCs
Molecular classification
Other
01

Overview

Human cutaneous antigen-presenting cells (APCs) are a specialized group of immune cells located within the skin layers, including epidermal Langerhans cells and various dermal dendritic cell subsets (Nestle et al., 2009, Nature Reviews Immunology). These cells serve as the primary sentinels of the peripheral immune system, responsible for capturing exogenous antigens, migrating to draining lymph nodes, and presenting these antigens to naive T cells to initiate adaptive immune responses (Kissenpfennig & Malissen, 2006, Biological Reviews). In clinical practice, cutaneous APCs are central to the pathophysiology of inflammatory skin diseases such as atopic dermatitis and psoriasis, where they contribute to chronic T-cell activation (StatPearls, Antigen Presenting Cells). They are also key targets for topical immunomodulators; for instance, Imiquimod acts as a TLR7 agonist to activate these cells for treating viral warts and basal cell carcinoma, while calcineurin inhibitors like Tacrolimus suppress their function to alleviate eczema (PubChem, Imiquimod; FDA, Protopic). Because this term refers to a diverse cellular population rather than a single protein, it is classified as a cellular target rather than a specific molecular receptor.

Other names
Skin-resident antigen-presenting cellsCutaneous APCsDermal dendritic cellsLangerhans cellsSkin APCs
02

Mechanism of action

Drugs targeting these cells typically act by modulating their maturation, migration, or ability to present antigens and secrete pro-inflammatory cytokines (e.g., TLR7 agonism by Imiquimod or calcineurin inhibition by Tacrolimus).

03

Biological functions

Antigen presentationImmune responseT-cell activationImmune surveillanceCytokine production
04

Disease associations

InflammationInfectionCancerAutoimmune diseasePsoriasisAtopic dermatitis
05

Safety considerations

Increased risk of skin infectionsSkin atrophySystemic immunosuppressionContact sensitization
06

Interacting drugs

Imiquimod

5 more in the full profile.

07

Biomarkers

CD1aCD207 (Langerin)HLA-DRCD11cCD80CD86CD14

Beyond the preview

Go deeper on Human cutaneous antigen-presenting cells (APCs) (APCs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human cutaneous antigen-presenting cells (APCs) (APCs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call